Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Antigenics commences first phase III trial of its Oncophage cancer vaccine

July 6, 2000

Biomira acquires remaining rights to Theratope from Chiron

July 4, 2000

Cancer immunotherapies based on WT-1 and gata-1 peptide epitopes

July 4, 2000

Cel-Sci receives permission to start phase II cancer trial in Canada

June 30, 2000

StressGen's HspE7 advances to phase III trials in anal dysplasia

June 28, 2000

FDA completes initial review of BLA for Campath

June 28, 2000

Lorus Therapeutics reports strong meta-analysis results for Virulizin, prepares for phase III trials

June 28, 2000

Tumor-associated antigen-derived immunogenic polypeptides useful for cancer immunotherapy

June 23, 2000

Mylotarg now available in U.S. as treatment for relapsed AML

June 22, 2000

Onyvax begins clinical trials for colorectal cancer vaccines

June 15, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...